Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Randomization question and data integrity
Richard confirms blinded randomization, explains non‑responder streak statistics, and defends study conduct.
Play episode from 21:39
Transcript
